Topic: checkpoint inhibitors
The Big Pharma has exercised its option on a discovery program but walked away from phase 1 LAG-3 PD-L1 bispecific FS118.
An Astra-Zeneca led research team has discovered a weakness in the process by which cancer cells to become resistant to MEK inhibition.
William Grossman joins the immuno-oncology biotech as it gears up for readouts from early-phase trials of its most advanced candidates.
Scientists at Boston Children's and MIT built CAR-T cells that are inspired by alpaca antibodies and can target protective proteins around solid tumors.
Two research groups have uncovered clues to immuno-oncology drug resistance, offering insight that could lead to new treatment strategies.
A CD40-activating antibody combined with BMS's Opdivo and chemo shrunk tumors in 20 out of 24 patients with pancreatic cancer.
CytomX's R&D update includes the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price.
The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors.
Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.
A new screening system confirmed that an emerging class of cancer drugs called IAP antagonists have immune-boosting powers.